How Cognizant’s AI-Powered Benchling Deployment at Kyowa Kirin (CTSH) Has Changed Its Investment StorySimplywall·15 hours agoCTSH-3.71%4151
Cognizant and Benchling Selected as Partners to Accelerate Kyowa Kirin's R&D | CTSH Stock NewsStockTitan·1 day ago, 01:00 PM4151CTSH-3.71%
Kura Oncology posts corporate presentation on KOMZIFTI launch, ziftomenib pipeline strategyPUBT·Aug 12 at 04:48 PMKURA+3.87%4151
Can Kyowa Kirin (TSE:4151) Sustain Its Stronger Profit Conversion And Evolving Investment Narrative?Simplywall·Aug 6 at 06:48 PM4151
Kyowa Kirin: Strong profit and revenue growth driven by global expansion and product performanceQuartr·Aug 3 at 01:40 AM4151
Kyowa Kirin EMEA’s Crysvita approved by EC for infants with XLHPharmaceutical Technology·Jul 22 at 04:41 AM4151
10:31 ETSystemic Lupus Erythematosus Market at a Turning Point as 6 Late-Stage Emerging Therapies Set to Redefine Treatment Landscape | DelveInsightprnewswire·Jul 9 at 09:31 AMNVS+0.72%BIIB-0.32%
How Investors Are Reacting To Kyowa Kirin (TSE:4151) Real-World Data On Mogamulizumab’s Patient BenefitsSimplywall·Jun 30 at 11:12 AM4151
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML | KURA Stock NewsStockTitan·Jun 10 at 11:02 PM4151KURA+3.87%
